{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T09:08:13.566724+00:00","company":{"ticker":"XBIT","cik":1626878,"company_name":"XBiotech Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"9dcdc2a8da","cik":1626878,"ticker":"XBIT","company_name":"XBiotech Inc.","filed_at":"2025-04-01T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2025-03-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"W. Thorpe McKenzie retired as Director at XBiotech Inc..","evidence_excerpt":"On March 27, 2025, W. Thorpe McKenzie informed the Board of Directors (the “Board”) of XBiotech Inc. (the “Company”) via letter of his decision to retire from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001876","anchor_url":"https://secwatch.observer/filing/0001171843-25-001876#claim-9dcdc2a8da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1626878/000117184325001876/0001171843-25-001876-index.htm"},{"fact_type":"debt_financing","fact_key":"13cf8ec04eec5bfc8d497b0f5a0b9dc43933e088","cik":1626878,"ticker":"XBIT","company_name":"XBiotech Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"counterparty":"John Simard","effective_date":"2024-01-03","event":"incurrence","instrument_type":"loan","interest_rate_text":"eight percent per year","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$10 million"},"claim":"XBiotech Inc. incurred loan of $10 million with John Simard at eight percent per year.","evidence_excerpt":"On January 3, 2024, XBiotech Inc. (“XBiotech” or the “Company”) entered into a Convertible Loan Agreement (the “Loan”) with John Simard, the Company’s Founder, President, Chief Executive Officer and Chairman. The Loan provides $10 million in immediate funding for the construction of a new, state-of-the-art research and development facility at 5217 Winnebago Lane in Austin, Texas. The Loan is secured by the real estate and cash holdings of the Company, with interest to accrue at a simple rate equal to eight percent per year and interest-only payments to be made at six-month intervals after the Loan is funded.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-24-000056","anchor_url":"https://secwatch.observer/filing/0001171843-24-000056#claim-13cf8ec04eec5bfc8d497b0f5a0b9dc43933e088","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1626878/000117184324000056/0001171843-24-000056-index.htm"},{"fact_type":"material_agreement","fact_key":"4f61e7817fce16e5c8701a19e89ebe1401ca77e1","cik":1626878,"ticker":"XBIT","company_name":"XBiotech Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Loan Agreement","agreement_type":"notes_offering","counterparty":"John Simard","effective_date":"2024-01-03","item_codes_triggered":["1.01"],"value_text":"$10 million"},"claim":"XBiotech Inc. entered into Convertible Loan Agreement with John Simard valued at $10 million (effective 2024-01-03).","evidence_excerpt":"On January 3, 2024, XBiotech Inc. (“XBiotech” or the “Company”) entered into a Convertible Loan Agreement (the “Loan”) with John Simard, the Company’s Founder, President, Chief Executive Officer and Chairman.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-24-000056","anchor_url":"https://secwatch.observer/filing/0001171843-24-000056#claim-4f61e7817fce16e5c8701a19e89ebe1401ca77e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1626878/000117184324000056/0001171843-24-000056-index.htm"}]}